annual report 2011-2012 11
FIP has adopted as one of its three main Strategic Objectives to
advance pharmacy practice in all settings. This ambitious goal is
done through the work of the nine Pharmacy Practice Sections,
which develop projects and initiatives to aid FIP and its Member
Organisations truly advance pharmacy practice on a global level.
Throughout this past year, the Board of Pharmaceutical Practice
(BPP) has continued to focus on its strategic and tactical
directions as health care systems, scientific discovery and
innovation and the evolution of pharmacy practice change.
Each of the BPP Sections has worked to align their directions
with the adopted BPP Strategic Plan and the FIPs Vision 2020.
This work will continue as a focus on the future of FIP becomes
clearer and more focused.
For more information on the work of each BPP Section please
click their titles below:
Academic Pharmacy Clinical Biology Community Pharmacy Hospital Pharmacy Industrial Pharmacy Laboratories and Medicines Control Military and Emergency Pharmacy Pharmacy Information Social and Administrative Pharmacy BPP has also worked with the Young Pharmacists Group (YPG)
Strong collaboration continues between the BPP and the Board
of Pharmaceutical Science. Building on discussions held between
the two boards executive committees, several areas have been
identified where collaboration is necessary; these include, pharmacovigilance/pharmacoepidemiology, pharmaceutical
waste/ecology, applied social and behavorial sciences and
nuclear pharmacy. The two Boards are presently exploring the
establishment of a joint working group on pharmaceuticals and
the environment. The latter is a broad and complex subject that
is gaining greater national and international attention. The two
Boards need to determine what the scope of our priorities and
interests should be on this subject.
Extensive discussions have been held by the BPP on the
evolving ethics, professionalism and autonomy issues facing
individual pharmacists in pharmacy practice. Increased focus by
governments on marketbased economies, global competitive
forces and costcontainment in the health care sector have the
capacity to compromise these important components of profes
sional life. A Working Group, cochaired by Dr. William Zellmer
and Dr. Betty Char, has been appointed to study these issues
and to issue a preliminary report of findings at the 2013 Dublin
Congress.
Board members Jacqueline Surugue and Dominique Jordan have
been requested to do further investigation of new and innova
tive economic models for pharmacist services reimbursement